Towards Healthcare
Embolization Particles Market Expands at 12.27% CAGR by 2034

Embolization Particles Market Competitive Forces and Top Key Players

Based on market forecasts, the embolization particles sector will expand from USD 1.19 billion in 2024 to USD 3.79 billion by 2034, experiencing a CAGR of 12.27%. The market is driven by growing demand for minimally invasive procedures and rising technological advancements like drug-eluting beads in chemotherapy. However, North America dominated the market with a major share due to the increasing instances of cancer, stroke, and peripheral vascular conditions, and advanced healthcare infrastructure.

Category: Biotechnology Insight Code: 5790 Format: PDF / PPT / Excel

Embolization Particles Market Size, Market Research and Forecast

The global embolization particles market size is calculated at US$ 1.19 in 2024, grew to US$ 1.34 billion in 2025, and is projected to reach around US$ 3.79 billion by 2034. The market is expanding at a CAGR of 12.27% between 2025 and 2034.

The global embolization particles market is experiencing significant expansion with merging technological advancements. Several factors, including growing cases of different cancers, peripheral vascular diseases, and uterine fibroids, increasing demand for minimally invasive procedures with their enhanced outcomes, reduced toxicity, and increased target treatment, are fueling the market growth. As per its accelerating applications in targeted diseases, opportunities such as personalized medicines, including customized particle size, shape, and improved delivery systems, are boosting demand for minimally invasive procedures and overall market growth.

Embolization Particles Market Size 2024 - 2034

Key Takeaways

  • The embolization particles market will likely exceed USD 1.19 billion by 2024.
  • Valuation is projected to hit USD 3.79 billion by 2034.
  • Estimated to grow at a CAGR of 12.27% starting from 2025 to 2034.
  • North America held the largest revenue share of the global embolization particles market share in 2024.
  • Asia Pacific is expected to be the rapidly growing region in the predicted period.
  • By product type, the radioembolization segment led the market in 2024.
  • By product type, the drug eluting beads segment is expected to grow at the fastest CAGR in the upcoming years.
  • By application, the oncology segment held the biggest revenue share of the market in 2024.
  • By application, the peripheral vascular disease segment is expected to grow fastest in 2025-2034.

Market Overview: Focus On Innovative Materials

Primarily, embolization particles are tiny, particularly employed in a minimally invasive procedure termed embolization, which helps to block or minimize blood flow in specific blood vessels. In 2025, the global embolization particles market will be driven by the increasing number of cancer and target disease cases, resulting in a growing demand for minimally invasive procedures such as embolization, which are primarily used to treat tumors and vascular abnormalities. Moreover, nowadays, the market is focusing on embolic agents for different conditions, coupled with optimizing their biocompatibility, targeting specific vessels, and escalating their ability to deliver therapeutic agents. As well as they are also exploring innovative materials, particle sizes, and delivery approaches to boost outcomes and reduce complications.

  • In March 2025, the government of Alberta invested $800 million by collaborating with Siemens Healthineers and Alberta Cancer Foundation to enhance cancer care with a rise in early detection of cancer. (Source - Siemens)
  • In February 2025, BridGene Biosciences, a leading player in the discovery of small-molecule drugs, made a strategic collaboration with Takeda, a Japanese multinational pharmaceutical company, to design small-molecule drugs for immunology and neurology targets. (Source - PR Newswire)
  • In November 2024, SINTX Technologies, Inc., an advanced ceramics company, signed a Joint Development Agreement (JDA) with NED Medical Inc., a pioneer of oncology embolization therapy technologies, to advance cutting-edge ceramic microsphere medical devices for cancer treatment. (Source - Globenewswire)

What are the Key Factors of AI Powering the Embolization Particles Market?

Currently, Globe is focusing on broad applications of AI in different sectors, including embolization. However, accelerating the adoption of minimally invasive procedures and growing developments of novel embolization particles, such as drug-eluting beads and bioresorbable materials, are fostering the use of AI algorithms for the same. AI has a crucial role in the market by increasing accuracy, improving procedures, and enhancing treatment outcomes. AI-driven tools assist in the analysis of medical images, estimate treatment responses, and customize treatment plans, resulting in highly effective and robust embolization therapies.

Market Dynamics

Driver

Fostering Demand for Minimally Invasive Procedures and Technological Advances

Around the world, embolization is a minimally invasive technique that has raised demand due to its minimized patient trauma, rapid recovery, and less need for hospital stays. Several embolic agents, like Polyvinyl alcohol (PVA) particles, Tris-acryl gelatin microspheres (TAGM), are used in this. Besides this, the global embolization particles market is fueled by rising technological advancements, including drug-eluting beads, like chemotherapeutic drugs, for localized treatment of tumors, and optimization in imaging modalities are boosting the efficacy of treatment and expansion of applications.

Restraint

Limitations for Cost and Safety

Emerging challenges across the market include for embolization to require well-developed devices, specialized embolic agents, and imaging support, which ultimately accelerate overall expenses. This rising spending generates limitations for patients. Along with this, sometimes this technique may create complications and side effects, and it also restricts the use of embolization.

Opportunity

Innovations in Material Science and Rising Applications

In prospects, there will be innovation in materials used in embolization, such as the development of biocompatible materials coupled with improved efficacy and safety profiles. These innovative materials are going to be widely employed in growing interest in areas like oncology, uterine fibroids, and prostate artery embolization. It is also focusing on the development of personalized procedures with tailored particle size, shape, and material properties for individual patient needs will be a key factor in the growth of the market.

Segmental Insights

How did the Radioembolization Segment Lead the Embolization Particles Market in 2024?

By product type, the radioembolization segment was dominant with the biggest revenue share of the market in 2024. The dominance of the segment is propelled by the increasing cases of liver cancer, peripheral vascular diseases, and uterine fibroids, which often demand radioembolization particles. Moreover, rising technological advancements and ultimate growth in interventional radiology procedures by utilizing embolization particles are expanding the overall market.

By product type, the drug eluting beads segment is expected to register rapid growth over the predicted timeframe. Major benefits of DEBs are in targeted drug delivery approaches such as they can deliver chemotherapy drugs directly to target tumor sites, which enhances effectiveness with reduced systemic exposure and side effects. Also, there are many developments like smaller DEBs with improved penetration capabilities that are optimizing treatment results and accelerating their applications across numerous areas.

Why did the Oncology Segment Hold a Major Revenue Share of the Market in 2024?

By application, the oncology segment dominated the global embolization particles market in 2024. In 2025 and the coming era, various types of cancer cases, especially liver, lung, and colorectal cancers, are and will be the major drivers of this segment. However, the growing adoption of TACE (Transarterial Chemoembolization) and TARE (Transarterial Radioembolization) is accelerating demand for embolization particles in different cancers with targeted treatments.

By application, the peripheral vascular disease segment is expected to be the fastest-growing in the upcoming years. Increasing incidences of peripheral artery disease (PAD), arteriovenous malformations (AVMS), and atherosclerosis are immensely demanding for embolization particle approaches. As well as, growing demand for minimally invasive procedures among patients and health professionals with enhanced benefits in recovery time and smaller incisions compared to open surgery is boosting the overall segment and market growth.

Regional Insights

What made North America dominate the Market in 2024?

North America led the global embolization particles market in 2024. Due to the high burden of cancer, stroke, and peripheral vascular conditions, are important for fueling the demand for embolization treatment. Along with this, the region is experiencing major growth by fostering a well-developed healthcare infrastructure, comprising advanced diagnostic technologies and specialized healthcare professionals, which boosts the adoption and application of embolization techniques.

The U.S. Embolization Particles Market Trends

The US is experiencing enormous technological advancements with rising demand for minimally invasive procedures among patients and physicians due to their significant benefits over open surgeries. Besides this, consistent innovations and enhanced embolization particles, delivery systems, and imaging techniques are accelerating the efficacy and safety of these approaches, hence supporting in overall US market growth.

For instance,

  • In June 2025, the IAEA (International Atomic Energy Agency) and MedAccess unveiled their partnership to escalate access to cancer care. (Source - International Atomic Energy Agency)

The Canada Embolization Particles Market Trends

The market is driven by the rising adoption of minimally invasive techniques, coupled with encouraging regulatory considerations in the form of approvals and simplifying processes for these approvals. Also, increasing investments in R&D and healthcare infrastructure to modernize healthcare facilities are expanding the market.

Expanding Population and Novel Adoption are Driving Asia Pacific

Asia Pacific is expected to grow at the fastest CAGR during the forecast period. As ASAP is experiencing the highest population growth connected with a variety of diseases, particularly different cancers, in developing countries like India, are a majorly demand for targeted, non-invasive procedures like embolization particles. As well as ongoing R&D activities for effective delivery systems and product launches are contributing to the overall ASAP market growth.

The India Embolization Particles Market Trends

In India, the increasing cases of different cancers with other conditions related to vascular and arterial conditions, are acting as a major driver for the market expansion. Along with this, the Indian government is highly encouraging to enhance public health and promote medical tourism is also playing a critical role in the market development.

For instance,

  • In December 2024, Mankind Pharma, a leading pharmaceutical company, collaborated with Innovent Biologics to commercialize Sintilimab, a cutting-edge PD-1 immunotherapy, in the Indian market. (Source - E Health)

The China Embolization Particles Market Trends

In China, especially live cancer instances are growing and are majorly impacting the demand for embolization particles. Whereas, China is a well-known country for novel developments in targeted therapies in cancer and other conditions, including minimally invasive techniques are propelling the ultimate market expansion.

For this market,

  • In December 2024, China's NMPA (National Medical Products Administration) approved EOM’s (East Ocean Medical (Hong Kong) Company Limited) coronary imaging system, which is based on Conavi Medical’s IP.(Source - Globenewswire)

Growing Adoption of Minimally Invasive Treatment is Driving Europe

Europe is estimated to grow significantly in 2025-2034, due to growing various conditions coupled with increasing demand and adoption of minimally invasive treatment, with its advantages across the diseases as compared to traditional approaches. Besides this, Europe has taken steps towards boosting awareness about health concerns, and embolization particles treatment in wide-range areas is also expanding the market growth.

The Germany Embolization Particles Market Trends

Germany has adopted high healthcare standards, which assist in the adoption of advanced medical techniques, including embolization. Also, the German government has initiated and accelerated favourable reimbursement policies for embolization procedures are boosting the market growth.

The UK Embolization Particles Market Trends

Rising demand for targeted therapies in growing targeted diseases like cancer, along with enhanced healthcare infrastructure and escalating patient awareness in embolization choice, is driving the UK market growth. Besides this, accelerating efforts in R&D to develop new and enhanced embolization particles are significantly impacting the market expansion.

For instance,

  • In April 2025, Ezra, a fintech infrastructure provider, launched an AI-driven complete-body MRI screening service in the UK. (Source - Gitex global)

Top Companies in the Embolization Particles Market

Embolization Particles Market Companies

Latest Announcements by Industry Leaders

  • In November 2024, the University of Texas MD Anderson Cancer Center, the Oden Institute for Computational Engineering and Sciences, and the Texas Advanced Computing Center (TACC) at The University of Texas announced its investment in six cancer research projects as part of the Joint Center for Computational Oncology. Tom Yankeelov, Ph.D., director of the Center for Computational Oncology at the Oden Institute, replied that this funding is going to support more than the previous year's projects. (Source - Mdanderson)
  • In November 2024, ARC Innovation announced a successful $5.1 million funding round for Starget Pharma, an early-stage clinical company, for a startup specialising in precise cancer diagnosis and targeted radiotherapy. CEO Sigal Clemenson-Kushnir commented that this investment will accelerate their radioligand-based technology to deliver safer and more effective treatments for complex cancers.

Recent Development in the Embolization Particles Market

  • In June 2025, Bangkok Heart Hospital launched a next-generation minimally invasive cardiac surgery program with mics CABG and 3d endoscopic valve surgery. (Source - MD Anderson)
  • In March 2025, Olympus Korea, a global company focused on medical technology, therapeutic intervention, and precision manufacturing, launched iTind, a minimally invasive solution for the treatment of patients with benign prostate enlargement (BPH). (Source - Koreabiomed)
  • In October 2024, Boston Scientific Corporation, a global player in medical technology leader that develops, manufactures, and markets medical devices launched AVVIGO™+ Multi-Modality Guidance System, a next-generation intravascular ultrasound (IVUS) and fractional flow reserve (FFR) system. (Source - Biospectrum India)

Segments Covered in the Report

By Product Type

  • Radioembolization
  • Drug Eluting Beads

By Application

  • Oncology
  • Peripheral Vascular Disease
  • Neurology

By Region 

  • North America
    • U.S.
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Thailand
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Sweden
    • Denmark
    • Norway
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East and Africa (MEA)
    • South Africa
    • UAE
    • Saudi Arabia
    • Kuwait
  • Last Updated: 30 June 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2023
  • Base Year: 2024
  • Estimated Years: 2025-2034

Meet the Team

Rohan Patil is a seasoned market research professional with over 5+ years of focused experience in the healthcare sector, bringing deep domain expertise, strategic foresight, and analytical precision to every project he undertakes.

Learn more about Rohan Patil

Aditi Shivarkar, with over 14 years of experience in consumer goods, leads research at Towards Consumer Goods, ensuring precise, actionable insights on trends, consumer preferences, and sustainable packaging for businesses.

Learn more about Aditi Shivarkar

Related Reports

FAQ's

The embolization particles market is projected to reach USD 3.79 billion by 2034, growing at a CAGR of 12.27% from 2024 to 2034.

North America is currently leading the embolization particles market due to the higher cases of cancer, stroke, and peripheral vascular conditions, and advanced healthcare infrastructure.

The embolization particles market includes 3 segments, such as by product type, by application, and by region etc.

Some key players include Boston Scientific Corporation, Cook Medical, Merit Medical Systems, Sirtex Medical, and BTG plc.

Key trends include rising demand for minimally invasive procedures, growth in applications in oncology and peripheral vascular disease, and innovation in embolic agents and other targeted treatments.

They are made of Polyvinyl alcohol (PVA), Gelatin sponge, Drug-eluting beads, Tris-acryl gelatin, and polyzene-F hydrogel.

The main purpose of embolization is to employ to stop bleeding or to block the flow of blood to a tumor or abnormal area of tissue.

The advantages of using DEBs in TACE are targeted delivery, sustained release, reduced toxicity, and enhanced outcomes.

NIH.GOV, CDC.GOV, GOV.UK, US FDA.GOV, MEDLINEPLUS.GOV, NCI.GOV